Study of Erlotinib and Metformin in Triple Negative Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Columbia University
Sponsor:
Collaborators:
Susan G. Komen Breast Cancer Foundation
Astellas Pharma Inc
Information provided by (Responsible Party):
Matthew A. Maurer, Columbia University
ClinicalTrials.gov Identifier:
NCT01650506
First received: July 24, 2012
Last updated: July 22, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2016
  Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)